Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 9:11:606744.
doi: 10.3389/fendo.2020.606744. eCollection 2020.

Clinical Application of AMH Measurement in Assisted Reproduction

Affiliations
Review

Clinical Application of AMH Measurement in Assisted Reproduction

Hang Wun Raymond Li et al. Front Endocrinol (Lausanne). .

Abstract

Anti-Müllerian hormone reflects the continuum of the functional ovarian reserve, and as such can predict ovarian response to gonadotropin stimulation and be used to individualize treatment pathways to improve efficacy and safety. However, consistent with other biomarkers and age-based prediction models it has limited ability to predict live birth and should not be used to refuse treatment, but rather to inform counselling and shared decision making. The use of absolute clinical thresholds to stratify patient phenotypes, assess discordance and individualize treatment protocols in non-validated algorithms combined with the lack of standardization of assays may result in inappropriate classification and sub-optimal clinical decision making. We propose that holistic baseline phenotyping, incorporating antral follicle count and other patient characteristics is critical. Treatment decisions driven by validated algorithms that use ovarian reserve biomarkers as continuous measures, reducing the risk of misclassification, are likely to improve overall outcomes for our patients.

Keywords: anti-Müllerian hormone; assisted reproduction; gonadotropin dosing; in vitro fertilization; intrauterine insemination; ovarian response.

PubMed Disclaimer

Conflict of interest statement

SN reports personal fees from Access Fertility, personal fees and non-financial support from Ferring, personal fees and non-financial support from Merck, personal fees from Coopers Genomics, personal fees and non-financial support from Ferring Pharmaceuticals, personal fees from The Fertility Partnership, grants, personal fees and non-financial support from Roche Diagnostics, personal fees from Modern Fertility, other from Delivery I, outside the submitted work. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

Cited by

References

    1. Hansen KR, Hodnett GM, Knowlton N, Craig LB. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil Steril (2011) 95(1):170–5. 10.1016/j.fertnstert.2010.04.006 - DOI - PubMed
    1. Nardo LG, Christodoulou D, Gould D, Roberts SA, Fitzgerald CT, Laing I. Anti-Müllerian hormone levels and antral follicle count in women enrolled in in vitro fertilization cycles: relationship to lifestyle factors, chronological age and reproductive history. Gynecol Endocrinol (2007) 23(8):486–93. 10.1080/09513590701532815 - DOI - PubMed
    1. Li HWR, Lee VCY, Lau EYL, Yeung WSB, Ho PC, Ng EHY. Role of baseline antral follicle count and anti-Mullerian hormone in prediction of cumulative live birth in the first in vitro fertilisation cycle: a retrospective cohort analysis. PLoS One (2013) 8(4):e61095. 10.1371/journal.pone.0061095 - DOI - PMC - PubMed
    1. Anderson RA, Anckaert E, Bosch E, Dewailly D, Dunlop CE, Fehr D, et al. Prospective study into the value of the automated Elecsys antimüllerian hormone assay for the assessment of the ovarian growing follicle pool. Fertil Steril (2015) 103(4):1074–80.e4. 10.1016/j.fertnstert.2015.01.004 - DOI - PubMed
    1. Fanchin R, Schonäuer LM, Righini C, Frydman N, Frydman R, Taieb J. Serum anti-Mullerian hormone dynamics during controlled ovarian hyperstimulation. Hum Reprod (2003) 18:328–32. 10.1093/humrep/deg043 - DOI - PubMed

Substances

LinkOut - more resources